Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
NCT02987959 · Fox Chase Cancer Center · PHASE2 · terminated · last registry update 2022-10-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed to accrual due to Funding Sponsor withdrawing support due to low accrual” | – | Registry record, Fox Chase Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-04Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Sapanisertib (NCT02142803)
- 2023-09-14Results posted on the registry: Genentech, Inc., Abiraterone + Apitolisib (NCT01485861)
- 2023-05-09Results posted on the registry: Joyce O'Shaughnessy, Tak-228 & Tak-117 + Cisplatin & Nab Paclitaxel (NCT03193853)
- 2023-05-03Results posted on the registry: National Cancer Institute (NCI), Navitoclax + Vistusertib (NCT03366103)
- 2023-02-08Also stopped (terminated): Calithera Biosciences, Inc, TAK-228 (NCT03370302)
- 2022-09-30Also stopped (withdrawn): Luke, Jason, MD, navoximod + NLG802 (indoximod Prodrug) (NCT05469490)
- 2022-09-27Results posted on the registry: NewLink Genetics Corporation, Pembrolizumab + Nivolumab (NCT03301636)
- 2022-09-27Also stopped (terminated): NewLink Genetics Corporation, Pembrolizumab + Nivolumab (NCT03301636)
- 2022-08-23Also stopped (terminated): National Cancer Institute (NCI), Pazopanib + Pazopanib Hydrochloride (NCT02601209)
- 2022-08-16Phase 3 first posted: Celcuity Inc, Gedatolisib + Palbociclib (NCT05501886)
- 2022-07-26Also stopped (terminated): Kathy Miller, MLN0128 + MLN0128 (RP2D) (NCT02575339)
- 2022-05-27Also stopped (withdrawn): M.D. Anderson Cancer Center, Nivolumab + Sapanisertib (NCT05022394)
- 2022-05-24Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT02484430)
- 2022-04-06Also stopped (terminated): NewLink Genetics Corporation, Docetaxel + Tergenpumatucel-L (NCT02460367)
- 2022-04-05Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT02893930)
- 2022-04-05Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT02417701)
- 2022-03-31Results posted on the registry: Kathy Miller, MLN0128 + MLN0128 (RP2D) (NCT02575339)
- 2022-02-24Results posted on the registry: Bradley A. McGregor, MD, TAK-228 (NCT03097328)
- 2022-01-19Results posted on the registry: University of Colorado, Denver, Alisertib + MLN0128 (NCT02719691)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision